Press Releases

 
Press Releases
  Date Title and Summary View
Mar 7, 2017
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2016. For the quarter ended December 31, 2016, the Company reported a net loss ...
Feb 24, 2017
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year 2016 before the market opens on Tuesday, March 7, 2017. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss the...
Feb 17, 2017
ArQule to host investor conference call on February 17, 2017 at 8:30 A.M. ET BURLINGTON, Mass., TOKYO, MUNICH, & PARSIPPANY, N.J.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo today announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular car...
Feb 8, 2017
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at The Leerink Partners 6th Annual Global Healthcare Conference on February 15th, 2017, ...
Dec 4, 2016
ARQ 531 demonstrates best-in-class potential as a reversible, non-covalent BTK inhibitor BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on Bruton's tyrosine kinase (BTK) inhibitor, ARQ 531, in a poster presentatio...
Dec 3, 2016
The study supports further exploration of ARQ 092 in sickle cell disease BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on its proprietary AKT inhibitor, ARQ 092, in an oral presentation by the University of Illin...
Nov 7, 2016
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2016. For the quarter ended September 30, 2016, the Company reported a net loss of...
Nov 3, 2016
BTK inhibitor, ARQ 531, potently inhibits wild type and C481S mutant BTK and is superior to ibrutinib in TCL1 mouse model for CLLAKT inhibitor, ARQ 092, has potential to treat Sickle Cell Disease BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today ...
Oct 24, 2016
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2016 before the market opens on Monday, November 7, 2016. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results an...
Sep 21, 2016
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28th, ...
Page:
1
... NextLast
= add release to Briefcase

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300